Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
Yousra Kherabi
, Mathilde Fréchet-Jachym, Christophe Rioux, Yazdan Yazdanpanah, Frédéric Méchaï, Valérie Pourcher, Jérôme Robert, Lorenzo Guglielmetti, and
for the MDR-TB Management Group
Author affiliations: Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (Y. Kherabi, C. Rioux, Y. Yazdanpanah); Sorbonne Université, INSERM U1135, Paris (Y. Kherabi, J. Robert, L. Guglielmetti); Centre Hospitalier de Bligny, Briis-sous-Forges, France (M. Frechet-Jachym); Assistance Publique—Hopitaux de Paris, Paris (C. Rioux, Y. Yazdanpanah); INSERM U1137, IAME, Université de Paris, Paris (Y. Yazdanpanah); Universite Paris Diderot, Paris (Y. Yazdanpanah); Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Paris (F. Méchaï); Hopital Avicenne, Bobigny, France (F. Méchaï); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris (V. Pourcher); Assistance Publique Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris (J. Robert, L. Guglielmetti)
Main Article
Figure
Figure. Kaplan–Meier curves of sputum time to culture conversion in fluoroquinolone-susceptible MDR TB and pre-XDR/XDR TB patients (log rank test p = 0.001). MDR, multidrug resistant (susceptible to all fluoroquinolones); pre-XDR/XDR, pre–extensively drug resistant/extensively drug resistant (resistant to >1 fluoroquinolone); TB, tuberculosis.
Main Article
Page created: July 31, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.